La Salpingo-oforectomía o Salpingectomía como estrategia para prevenir el cáncer de ovario
DOI:
https://doi.org/10.58296/rm.v27i1.29Keywords:
Salpingectomia, Ooforectomia, cáncer, mutaciones BRCA1, BRCA2Abstract
Se dispone de abundante información relacionada con la carcinogénesis de los tumores epiteliales de ovario de alto grado, sabiéndose hoy que la mayoría de los carcinomas serosos de alto grado, endometriodes y de células claras del ovario derivan de la trompa de Falopio y no directamente del ovario. En esta revisión se pretende determinar si la extirpación de las trompas de Falopio sin ooforectomia puede permitir a las mujeres que tienen mutaciones BRCA1 o BRCA2 reducir su riesgo de cáncer de ovario y al mismo tiempo evitar la menopausia precoz y mantener su calidad de vida. Se ha desarrollado una teoría en relación con que la salpingectomía sola en mujeres que tienen mutaciones BRCA1 o BRCA2 y en aquellas que se desconozca si poseen esta mutación ofrecería una excelente alternativa para disminuir el riesgo de cáncer de ovario.
Metrics
References
Ferlay J, Shin B, Bray F, et al. Globocan 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10[internet]. Lyon, France. In: International Agency for Research on Cancer; 2010. [http://www.eurosafeimaging.org/wp/wpcontent/uploads/2015/05/Global-CancerStatistics.pdf]
Lowe K, Chia V, Taylor A, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013;130:107- 14. [https://pubmed.ncbi.nlm.nih.gov/23558050/] DOI: https://doi.org/10.1016/j.ygyno.2013.03.026
American Cancer Society,2007. Cancer Facts and Figures. [ www.cancer.org.Links ]
Ferlay J, Shin B, Bray F, et al. Globocan 2008 v 2.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [internet]. Lyon, France. In: International Agency for Research on Cancer; 2010 [ http://www.eurosafeimaging.org/wp/wp-content/uploads/2015/05/Global-Cancer-Statistics.pdf]
Vang R, Shih I, Kurman R. Ovarian lowgrade and high-grade serous carcinoma:Pathogenesis, clinic pathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009,16:267-82. [ https://www.remedypublications.com/open-access/mucinous-differentiation-in-a-high-gradeserous-epithelial-ovarian-carcinoma-7871.pdf] DOI: https://doi.org/10.1097/PAP.0b013e3181b4fffa
Gómez-Pue D,1 Ibarrola-BuenAbad E,2 Lara-Núñez D,2 Vázquez-Alvarado AP,2 Pérez-Quintanilla M1. Salpingectomía como
opción de reducción del riesgo de cáncer de ovario. https://www.medigraphic.com/cgibin/new/resumen.cgi?IDARTICULO=73226
Foulkes WD. Preventing ovarian cancer by salpingectomy. Curr Oncol 2013;20(3):139-42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671016/ DOI: https://doi.org/10.3747/co.20.1613
JILL DELSIGNE-RUSSELL. La extirpación de las trompas de Falopio puede reducir el riesgo del cáncer de ovario [ https://www.mdanderson.org/es/publicaciones/oncolog/febrero-2017/laextirpacion-de-las-trompas-de-falopio-puedereducir-el-riesgo.html]
Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA (2012). Prediction of BRCA1 germline mutation status in
women with ovarian cancer using morphologybased criteria. Identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol
:1170-1177. https://pubmed.ncbi.nlm.nih.gov/22790858/
Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the
fallopian tube. Gynecol Oncol 2001;80(3):341–5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422129/ DOI: https://doi.org/10.1006/gyno.2000.6095
Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J
Cancer 2011;105(suppl 2):S77–81. [ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3252065/]
CRUK. Ovarian cancer risk factors. Available at: http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-by-cancertype/ovarian-cancer#heading-Three. Retrieved July 23, 2017. [ https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/risks-causes]
Havrilesky LJ, Moorman PG, Lowery WJ,Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive pills asprimary prevention for
ovarian cancer: a systematic review and metaanalysis. Obstet Gynecol 2013; 122:139–47. [https://pubmed.ncbi.nlm.nih.gov/23743450/]
Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2
carriers: a meta-analysis. Eur J Cancer 2010; 46:2275–84. [ https://www.ncbi.nlm.nih.gov/books/NBK78737/] DOI: https://doi.org/10.1016/j.ejca.2010.04.018
Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. Menopausal
hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological
studies. Lancet 2015; 385:1835–42. https://www.nature.com/articles/bjc201735 DOI: https://doi.org/10.1016/S0140-6736(14)61687-1
Manual SEOM de prevención y diagnóstico precoz del cáncer. https://seom.org/manualprevencion/211/#zoom=z
Sung HK, Ma SH, Choi JY, Hwang Y, Ahn C, Kim BG, et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis. J Prev Med Public Health 2016; 49:349–66. [ https://pubmed.ncbi.nlm.nih.gov/27951628/] DOI: https://doi.org/10.3961/jpmph.16.066
Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and
borderline ovarian tumors: a nationwide casecontrol study. Acta Obstet Gynecol Scand 2015; 94:86–94. [ https://pubmed.ncbi.nlm. DOI: https://doi.org/10.1111/aogs.12516
nih.gov/25256594/]
Haruta S, Furukawa N, Yoshizawa Y, et al. Molecular genetics and epidemiology of epithelial ovarian cancer (Review). Oncol
Reports 2011; 26:1347-56. [ https://pubmed.ncbi.nlm.nih.gov/21922146/]
Brewer M, Johnson K, Follen M, et al.Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003; 9:20-30. [ http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75262015000500011]
Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A
metaanalysis. Eur J Cancer. 2016 Mar; 55:38-46. https://www.acog.org/clinical/clinicalguidance/committee-opinion/articles/2019/04/
opportunistic-salpingectomy-as-a-strategy-forepithelial-ovarian-cancer-prevention
Kho RM, Wechter ME. Operative Outcomes of Opportunistic Bilateral Salpingectomy at the Time of Benign Hysterectomy in LowRisk Premenopausal Women: A Systematic Review. J Minim Invasive Gynecol. 2017 Feb;24(2):218-229. [https://pubmed.ncbi.nlm. DOI: https://doi.org/10.1016/j.jmig.2016.12.004
nih.gov/27988392/]
Kurman RJ, Shih I. The dualistic model of ovarian carcinogenesis: revisited, revised, and
expanded. Am J Pathol 2016; 186:733–47. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808151/]
Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and
concurrent pelvic high-grade serous [ https://pubmed.ncbi.nlm.nih.gov/21990067/]
Eva Ruvalcaba-Limón, Araceli SilvaGarcía, Carlos Eduardo Aranda-Flores, Félix Quijano-Castro, Joel BañuelosFlores, Gonzalo Montalvo-Esquivel y Milagros Clementina Pérez-Quintanilla.Factores de riesgo, factores protectores y etapificación [ https://biblat.unam.mx/hevila/
Gacetamexicanadeoncologia/2018/vol17/supl2/1.pdf]
Factores de Riesgo del Cáncer de Ovario.
Gustavo Romero Gutiérrez, Jaime Naves
Sánchez, Alejandra Horna López, Carlos Julio
Aspe Lucero, Roberto Molina Rodríguez,
Ana Lilia Ponce Ponce de León. Factores de
riesgo asociados con cáncer de ovario. https://
www.medigraphic.com/cgi-bin/new/resumen.
cgi?IDARTICULO=6472
Laura Yuriko González-Teshima; Fabio
Samir Vargas-Cely; Juan Sebastián MuñozSandoval, MD; Julián Ramírez-Cheyne, MD ;
Wilmar Saldarriaga-Gil, MD, MSc. Síndrome
de cáncer hereditario de mama y ovario:
aplicación clínica [ http://www.scielo.org.co/
scielo.php?script=sci_arttext&pid=S0034-
#:~:text=El%20
s%C3%ADndrome%20de%20
c%C3%A1ncer%20hereditario%20
de%20mama%20y%20ovario%20
(SCHMO,BRCA2%20localizados%20en%20
el%20cromosoma]
Cristina Isabel Martínez1, Luis Francisco
Pérez1, David Baquero2, Andrés Barco2.
Cáncer colorrectal hereditario no asociado a
poliposis o síndrome de Lynch. Rev Colomb
Cir. 2017; 32:297-303 [ http://www.scielo.org. DOI: https://doi.org/10.30944/20117582.38
co/pdf/rcci/v32n4/v32n4a9.pdfLinks ]
Sindrome de Peutz y Jeghers [ https://
www.cancer.net/cancer-types/peutz-jegherssyndrome#:~:text=PJS%20is%20a%20
genetic%20condition,known%20as%20the%20
LKB1%20gene. ]
Sampson JR, Dolwani S, Jones S, Eccles D,
Ellis A, Evans DG, et al. Autosomal recessive
colorectal adenomatous polyposis due to
inherited mutations of MYH. Lancet. 2003;
:39-41. [ https://pubmed.ncbi.nlm.nih.
gov/12853198/]
https://www.elsevier.es/es-revistaprogresos-obstetricia-ginecologia-151-
articulo-estimulacion-folicular-ovarica-riesgocancer-13009680
https://www.cdc.gov/spanish/especialescdc/
cancereshereditarios/index.html Cáncer de
mama y de ovario hereditarios
Nicolás Padilla-Raygoza, Rebeca MonroyTorres, Cuauhtémoc SandovalSalazar, Luz
Elvia Vera-Becerra, María Esther Patiño-López,
María de Lourdes García-Campos y otros.
Programas de prevención de cáncer en México:
¿estamos haciendo lo suficiente? [ https://
ecancer.org/es/journal/article/997-cancerprevention-programmes-in-mexico-are-wedoing-enough/pdf/es]
Hartmann LC, Lindor NM. The role of
risk-reducing surgery in hereditary breast and
ovarian cancer. N Engl J Med 2016374:454–68. [
https://pubmed.ncbi.nlm.nih.gov/27305204/]
Marchetti C, De Felice F, Palaia I, Perniola G,
Musella A, Musio D, et al. Risk-reducing salpingooophorectomy: a meta-analysis on impact on
ovarian cancer risk and all-cause mortality in
BRCA 1 and BRCA 2 mutation carriers. BMC
Womens Health 2014; 14:150. https://www.ncbi.
nlm.nih.gov/pmc/articles/PMC4271468/
Leblanc E, Narducci F, Farre I, Peyrat JP,
Taieb S, Adenis C, et al. Radical fimbriectomy:
a reasonable temporary riskreducing surgery for
selected women with a germ line mutation of
BRCA 1 or 2 genes? Rationale and preliminary
development. Gynecol Oncol 2011; 121:472–6. [
https://pubmed.ncbi.nlm.nih.gov/21411127/]
Finch A, Beiner M, Lubinski J, Lynch HT,
Moller P, Rosen B, et al. Salpingo-oophorectomy
and the risk of ovarian, fallopian tube, and
peritoneal cancers in women with a BRCA1 or
BRCA2 mutation. JAMA 2006; 296:185–92. [ DOI: https://doi.org/10.1001/jama.296.2.185
https://pubmed.ncbi.nlm.nih.gov/16835424/]
Falconer H, Yin L, Gronberg H, Altman
D. Ovarian cancer risk after salpingectomy: a
nationwide population-based study. J Natl Cancer
Inst 2015 Jan 27. [https://europepmc.org/article/
med/25628372].
Darelius A, Lycke M, Kindblom JM,
Kristjansdottir B, Sundfeldt K, Strandell A.
Efficacy of salpingectomy at hysterectomy to
reduce the risk of epithelial ovarian cancer: a
systematic review. BJOG 2017;124:880–9. [ DOI: https://doi.org/10.1111/1471-0528.14601
https://obgyn.onlinelibrary.wiley.com/doi/
abs/10.1111/1471-0528.14601]
Manchanda R. Opportunistic salpingectomy
for prevention of ovarian cancer. BJOG 2017;
:890. [ Links ]
Ying Chen , Hui Du , Lewen Bao y Wenxin
Liu. Salpingectomía oportunista en cirugía
ginecológica benigna para reducir el riesgo de
cáncer de ovario: una experiencia de 10 años
en un solo centro de China y una revisión de la
literatura
Vang R, Shih I, Kurman R. Ovarian low-grade
and high-grade serous carcinoma: Pathogenesis,
clinic pathologic and molecular biologic features,
and diagnostic problems. Adv Anat Pathol
,16:267-82. [ https://pubmed.ncbi.nlm.
nih.gov/19700937/]
Guía de práctica clínica en cáncer hereditario
de la Comunitat Valenciana. Tercera edición. 2017.
Conselleria de Sanitat Universal I Salut Pública
Generalitat. [https://portal.guiasalud.es/gpc/
cancer-hereditario/] [Consulta: 03/05/2021]
Jacobson M, Coakley N, Bernardini M,
Elit L, Ferguson SE, Kim R. Risk Reduction
Strategies for BRCA1/2 Hereditary Ovarian
Cancer Syndromes Toronto (ON): Ontario
Health (Cancer Care Ontario); 2020 September
Program in Evidence-Based Care Guideline
No.: 4-4. https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC8474940/Version [https://
www.cancercareontario.ca/en/file/56691/
download?token=nZtHkYf7] [Consulta:
/05/2021]
Kwon JS, Tinker A, Pansegrau G, McAlpine
J, Housty M, McCullum M, et al. Prophylactic
salpingectomy and delayed oophorectomy as an
alternative for BRCA mutation carriers. Obstet
Gynecol 2013; 121:14–24. [ https://europepmc. DOI: https://doi.org/10.1016/j.neucom.2013.01.030
org/article/med/23232752]
Anderson M. Prophylactic salpingectomy with
delayed oophorectomy, risk-reducing salpingooophorectomy, and ovarian cancer screening
among BRCA mutation carriers: a proof-ofconcept study (study #2013-0340). Available at:
https://www.mdanderson.org/patients-family/
diagnosis-treatment/clinical-trials/clinical-trialsindex/clinical-trials-detail. ID2013-0340.html.
Retrieved July 23, 2017.
Veiga-Fernández, Amanda, Luque-Molina,
María del Sol,, Ferreres-García, Karla1
Mendizábal-Vicente, Elsa María Rincón-Olbes,
Patricia
Lizárraga-Bonelli, Santiago [ https://www.
scielo.org.mx/scielo.php?pid=S0300-
&script=sci_arttext_
plus&tlng=es Links ]
McAlpine J, Hanley G, Woo M, et al. Ovarian
cancer research program of British Columbia.
Opportunistic salpingectomy: uptake, risks, and
complications of a regional initiative for ovarian
cancer prevention. Am J Obstet Gynecol 2014;
:471. e1-e11. [ https://www.ajog.org/article/
S0002-9378%2814%2900014-3/abstract ]
Mohamed AA, Yosef AH, James C, AlHussaini TK, Bedaiwy MA, Amer SAKS. Ovarian
reserve after salpingectomy: a systematic review
and meta-analysis. Acta Obstet Gynecol Scand
; 96:795–803. [https://obgyn.onlinelibrary.
wiley.com/doi/pdf/10.1111/aogs.13133 ]
Gan C, Chenoy R, Chandrasekaran D,
Brockbank E, Hollingworth A, Vimplis S, et
al. Persistence of fimbrial tissue on the ovarian
surface after salpingectomy. Am J Obstet Gynecol
; 217:425. e1–16. [ https://www.wjgnet.
com/2218-4333/CitedArticlesInF6?id=10.1111%
Fhis.12419]
Nowak M, Janas Ł, Stachowiak G, Stetkiewicz
T, Wilczyński JR. Current clinical application
of serum biomarkers to detect ovarian cancer.
Prz Menopauzalny. 2015;14(4):254-9. [Current DOI: https://doi.org/10.9785/gesr-2015-0410
clinical application of serum biomarkers to detect
ovarian cancer. - Abstract - Europe PMC ]
https://www.aarp.org/espanol/salud/expertos/
elmer-huerta/info-2016/talco-y-minerales-quecausan-cancer.html
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Revista Medica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
